Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
What the clinical evidence shows Several large, peer-reviewed studies have quantified the risk: The STEP 1 trial (NEJM, 2021): patients on high-dose semaglutide lost an average of 14.9% of their body weight over 68 weeks
1 The same mechanisms apply to the hip, which carries 2.5 to 3 times body weight when walking, so the benefit is biologically plausible, but Wegovy hasnt been tested in a published hip trial
It is not just about willpower
But it is important to remember: GHK-Cu is not magic
Within the GLP-1 receptor agonist class , other options available in the UK include: Dulaglutide (Trulicity) weekly injection with proven cardiovascular benefits [12] [17] Liraglutide (Victoza) daily injection with proven cardiovascular benefits [13] Exenatide (Byetta) twice-daily injection Exenatide extended-release (Bydureon) weekly injection Lixisenatide (Lyxumia) daily injection Tirzepatide (Mounjaro) weekly injection that acts on both GLP-1 and GIP receptors [14] [15] Whilst these medications share similar mechanisms to semaglutide, individual tolerability varies
